HHS Report Exposes Multi-Million Fraud in Gender Care

Summary:

The U.S. Department of Health and Human Services has released a commissioned report examining how hospitals and clinics expanded experimental sex-rejecting interventions on minors and generated long-term revenue from them. Titled Wolves in White Coats: How Doctors and Hospitals Pushed and Profited from the Fraud of “Gender Medicine,” the document argues that thin margins in pediatrics, expansive professional guidelines, and prior federal policy combined to create a model of lifelong “captive” patients. It documents alleged systematic use of alternative diagnostic codes to obtain insurance and Medicaid payment, details first-hand accounts of rapid affirmation and later harm, and describes the role of major medical societies in lowering clinical barriers. On 11 August the administration finalised a rule ending federal Medicaid and Children’s Health Insurance Program funding for puberty blockers, cross-sex hormones and surgeries for minors. Two days later, on the day the report was published, Vice President JD Vance and Health Secretary Robert F. Kennedy Jr. referred hospitals and clinics identified in the report to the Department of Justice and the HHS Office of Inspector General.

Detailed Report

1. Core Findings of the HHS Report on Pediatric Gender Medicine

On 13 August 2026 the Department of Health and Human Services published Wolves in White Coats: How Doctors and Hospitals Pushed and Profited from the Fraud of “Gender Medicine.” The full report is available at https://www.hhs.gov/sites/default/files/hhs-wolves-in-white-coats.pdf.

The 64-page document examines the institutional drivers behind the rapid expansion of puberty blockers, cross-sex hormones and surgeries for minors. Its core findings are:

• that pediatric gender programmes created a high-margin, multi-decade revenue stream by converting otherwise healthy minors into patients requiring continuous care;

• that providers allegedly used non-gender-specific diagnostic codes to unlock insurance and Medicaid payment when gender-dysphoria codes faced restrictions;

• that major professional societies moved from earlier caution to expansive guidelines with substantial membership overlap; and

• that prior federal policy actively expanded access and coverage.

First-hand accounts from patients and parents are presented as evidence of the real-world consequences of rapid affirmation with limited evaluation. Contributors include surgeon Dr. Eithan Haim, pediatric endocrinologist Dr. Quentin Van Meter and psychiatrist Dr. Aaron Kheriaty. The report concludes that the combination of financial incentives, professional guidelines and policy produced conditions for potential large-scale fraud and that the patterns identified are “only the tip of the iceberg.”

2. Alleged Billing Fraud and the Lifelong Profit Motive

Pediatrics traditionally operates on thinner margins than many other specialties. The report argues that gender clinics altered that calculus by creating long-term, multi-specialty patients. Guidelines from the Endocrine Society and the World Professional Association for Transgender Health (WPATH) recommend clinical assessments every three to six months, laboratory monitoring every six to twelve months, and bone-density scans every one to two years, continuing into adulthood. Lifetime costs are estimated at $25,000 to $75,000 even without surgery and can approach $170,000 when surgeries are included. Aggregate billed charges for minors from 2019 onward are estimated at nearly $120 million nationwide. Mount Sinai Medical Center and Boston Children’s Hospital are cited among the highest-volume programmes.

Against this background, the report examines billing practices. Many insurers and Medicaid programmes restricted or scrutinised gender-dysphoria codes. Providers are alleged to have responded by using alternative codes, particularly E34.9 (endocrine disorder, unspecified) and codes for central precocious puberty. HHS claims analysis for 2015–2025 identified nearly $50 million billed under endocrine-disorder diagnoses for patients aged 9–17, the large majority under E34.9. A further $11 million was billed under the precocious-puberty code for patients aged 13–17, an age at which puberty is not considered precocious. A University of Iowa study found that only 4.7 per cent of patients coded with E34.9 actually had an endocrine condition.

The report documents advocacy materials and clinician discussions that recommended alternative codes explicitly for insurance purposes. It frames these patterns as potential fraud under the False Claims Act and related statutes. Two enforcement outcomes are highlighted. In May 2026 Texas Children’s Hospital agreed to a $10 million settlement with the Texas Attorney General and the Department of Justice over alleged false diagnosis codes used for Medicaid billing; the settlement required staff terminations, bylaw changes and the creation of a hospital-funded detransition clinic. In June 2026 the Cleveland Clinic Foundation reached a monetary settlement and committed $2 million for restorative care.

3. How Medical Societies Lowered Barriers to Gender Interventions

The report examines how major medical organisations shifted from earlier caution to expansive positions. The World Professional Association for Transgender Health (WPATH) moved from standards that restricted hormonal and surgical interventions primarily to adults toward Standards of Care Version 8, which endorsed puberty blockers and cross-sex hormones from the onset of puberty and permitted certain surgeries previously reserved for adults. The Endocrine Society’s 2017 clinical practice guideline was produced by a group in which at least seven of ten authors had WPATH affiliations; it suggested puberty suppression and noted limited published evidence for early hormone treatment. The American Academy of Pediatrics (AAP) 2018 policy statement was drafted primarily by one author, approved by the 13-member board without input from the general membership of approximately 67,000 pediatricians, and labelled exploratory mental-health approaches as unethical. The board later reaffirmed the statement while the Academy’s own systematic evidence review remained incomplete. The American Psychological Association (APA) 2015 guidelines prioritised “trans-affirmative” practice and were developed by a task force with extensive WPATH links.

The report’s critique is that these organisations, with substantial overlap of authors and members, reduced clinical gatekeeping, framed dissent as unethical, and thereby shaped hospital protocols and clinician behaviour across the country. Roughly 225 hospitals and health systems have established pediatric gender programmes.

4. Patient Accounts of Rapid Affirmation and Lasting Harm

The report presents detailed interviews that illustrate common patterns: rapid affirmation after limited evaluation, minimal exploration of trauma, autism or co-occurring mental-health conditions, inadequate risk disclosure, and difficulty obtaining support after detransition.

Sydney Aviles was referred at 14 after early puberty, sexual assault and family breakdown. She underwent a double mastectomy at 18 and later detransitioned, reporting ongoing thyroid dysfunction and difficulty finding clinicians experienced in post-detransition care. Clementine Breen was told at age 12 she was “100 per cent trans” and at high risk of suicide. She received a puberty blocker at 12, testosterone at 13 and a double mastectomy at 14. Dosage was later increased; she experienced psychosis, self-harm and severe psychiatric deterioration. After processing childhood sexual abuse in therapy she detransitioned at 18 and continues to report irregular cycles, vaginal atrophy, chest pain and nerve issues. Providers became unresponsive once she stated she was detransitioning.

Layla Jane, who had undiagnosed autism, anxiety and depression, received a puberty blocker at 12, testosterone at 13 and a double mastectomy one month after her 13th birthday. Parents were told the choice was a “live son or a dead daughter.” She later experienced liver abnormalities, joint pain, urinary dysfunction and chronic nerve pain. A medical malpractice claim was dismissed on procedural grounds. Other accounts describe autistic adolescents rapidly affirmed, parents who found few domestic clinicians willing to support exploratory approaches, and long-term physical complications including infertility risks, sexual dysfunction and ongoing endocrine problems.

5. Medicaid and CHIP Funding for Gender Care Ended for Minors

On 11 August 2026 the Centers for Medicare & Medicaid Services finalised a rule prohibiting federal Medicaid funding for sex-rejecting procedures on individuals under 18 and federal Children’s Health Insurance Program funding for the same procedures on individuals under 19. The rule takes effect on 13 October 2026. A six-month tapering period is permitted for those already receiving cross-sex hormones. Mental-health treatment remains covered. States may continue the interventions with state-only funds.

HHS Secretary Robert F. Kennedy Jr. stated: “Today, we are ending federal taxpayer funding for sex-rejecting procedures on children. These interventions carry serious risks and can cause irreversible harm. The federal government will no longer use Medicaid and CHIP dollars to fund procedures that fail to meet the evidentiary standard our children deserve.”

CMS Administrator Dr. Mehmet Oz said: “Children deserve our protection, not experimental interventions that pose serious risks and convey no proven benefits. By cutting off federal funds for these sex-rejecting procedures, we’re following the science, saving taxpayer dollars, and, most importantly, protecting children from potentially irreversible harm so they can truly flourish.”

President Trump posted the full statement: “Today, at my direction, Dr. Mehemet Oz announced that Medicaid will NO LONGER fund gender transition surgeries and hormones for minors. We are not going to pay for our innocent children to undergo these barbaric surgeries and practices, which result in unthinkable and irreversible harm to their young bodies. Thanks to our strong position and pressure on this issue over the past year and a half, dozens of U.S. hospitals have already ended this so-called “gender-affirming care,” and we expect many more to follow. Just think about all of the young, innocent, and perhaps confused children who will be spared! While the Dumocrat Party wants your kids to be able to chop off their reproductive organs before they are old enough to vote, President Donald J. Trump (ME!) and the Republican Party say that is ABSURD, and we will protect America’s children. Please remember this when you are casting your vote in the Midterm Elections in November. Thank you for your attention to this very important matter! President DONALD J. TRUMP”

A separate proposed rule that would bar hospitals from performing these interventions on minors as a condition of Medicare and Medicaid participation remains under review, with a target finalisation in December 2026.

6. Vance and Kennedy Refer Gender Clinics for Federal Investigation

On 13 August 2026, the same day the report was released, Vice President JD Vance, acting as Chairman of the White House Fraud Task Force, and Secretary Kennedy formally referred hospitals and clinics identified in the report to the Department of Justice and the HHS Office of Inspector General. Vance’s letter to Attorney General Todd Blanche stated that providers who intentionally miscoded treatments to obtain coverage for interventions that would otherwise have been denied “should go to prison.” The referral cites the financial incentives, coding patterns and patient harms documented in the report.

Conclusion

Wolves in White Coats presents a detailed case that financial incentives rooted in thin pediatric margins, expansive professional guidelines, and prior federal policy combined to expand experimental interventions on minors while creating multi-decade revenue streams. It documents alleged coding practices used to unlock payment, records the experiences of patients who later detransitioned, and concludes that the patterns identified point to potential large-scale fraud. Concurrent administrative actions have ended federal Medicaid and CHIP funding for these interventions on minors and referred identified institutions for investigation. Readers now have a clear public record of both the report’s findings and the government’s immediate response.